pain drug potential

Weight loss drug did not work, so its only natural that investors who carried positions into the trading halt, would scratch around and potentially could , in their own minds....... form a rose coloured view of whats left of the company.

Of course, best approach by far (especially from long term full time traders)....in the cold light of day would be to assess MBP's other drugs and either decide to sell or mayby retain their now low value holdings and "hope for the best".

I fit into a different catergy to the above. Having undertaken detailed research on the phase 2 pain drug...... am buying strongly at these levels.

Their drug ACV works by blocking pain in nerve receptors without any effect on nerve channels....(these channel send signals to the brain which causes side effects-when other current moderatily successful drugs are used) .

There is some chance that ultimitly ACV1 may have this market on its own.

Lots of research over the years has been done on cone shells....including a product that is currently in the market for pain control. ......it iworks as a contoxin, which travels to the brain (side effects).

Only MBP has patients for a modified cone shell toxin which works to block nerve receptors.......rather than the N channel itself.